A subsequent phase I trial of CIML NK cells from haploidentical donors followed by IL-2 administration for patients with relapsed and refractory acute myeloid leukemia (AML) who had never undergone allogeneic transplantation demonstrated a complete remission (CR) and CR with incomplete hematologic recovery (CRi) rate of 50%. Here, IL2 is linked to acute myeloid leukemia.